Department of Cardiothoracic and Respiratory Sciences, Second University of Naples via Pansini N. 5, 80131 Naples, Italy.
J Clin Endocrinol Metab. 2012 Oct;97(10):3684-90. doi: 10.1210/jc.2012-2269. Epub 2012 Aug 1.
Antipituitary antibodies (APA) but not antihypothalamus antibodies (AHA) are usually searched for in autoimmune hypopituitarism.
Our objective was to search for AHA and characterize their hypothalamic target in patients with autoimmune hypopituitarism to clarify, on the basis of the cells stained by these antibodies, the occurrence of autoimmune subclinical/clinical central diabetes insipidus (CDI) and/or possible joint hypothalamic contribution to their hypopituitarism.
We conducted a cross-sectional cohort study.
Ninety-five APA-positive patients with autoimmune hypopituitarism, 60 without (group 1) and 35 with (group 2) lymphocytic hypophysitis, were studied in comparison with 20 patients with postsurgical hypopituitarism and 50 normal subjects.
AHA by immunofluorescence and posterior pituitary function were evaluated; then AHA-positive sera were retested by double immunofluorescence to identify the hypothalamic cells targeted by AHA.
AHA were detected at high titer in 12 patients in group 1 and in eight patients in group 2. They immunostained arginine vasopressin (AVP)-secreting cells in nine of 12 in group 1 and in four of eight in group 2. All AVP cell antibody-positive patients presented with subclinical/clinical CDI; in contrast, four patients with GH/ACTH deficiency but with APA staining only GH-secreting cells showed AHA targeting CRH- secreting cells.
The occurrence of CDI in patients with lymphocytic hypophysitis seems due to an autoimmune hypothalamic involvement rather than an expansion of the pituitary inflammatory process. To search for AVP antibody in these patients may help to identify those of them prone to develop an autoimmune CDI. The detection of AHA targeting CRH-secreting cells in some patients with GH/ACTH deficiency but with APA targeting only GH-secreting cells indicates that an autoimmune aggression to hypothalamus is jointly responsible for their hypopituitarism.
在自身免疫性垂体功能减退症中,通常会寻找抗垂体抗体(APA),而不是抗下丘脑抗体(AHA)。
我们的目的是在自身免疫性垂体功能减退症患者中寻找 AHA,并对其下丘脑靶标进行特征分析,根据这些抗体染色的细胞,阐明是否存在亚临床/临床中枢性尿崩症(CDI)的自身免疫性疾病,以及(或)其垂体功能减退症是否可能与下丘脑共同发病。
我们进行了一项横断面队列研究。
95 例 APA 阳性的自身免疫性垂体功能减退症患者,其中 60 例无(第 1 组)和 35 例伴淋巴细胞性垂体炎(第 2 组),与 20 例术后垂体功能减退症患者和 50 例正常对照进行了比较。
通过免疫荧光法检测 AHA,评估后叶垂体功能;然后用双重免疫荧光法检测 AHA 阳性血清,以鉴定 AHA 靶向的下丘脑细胞。
第 1 组 12 例患者和第 2 组 8 例患者中检测到高滴度 AHA。在第 1 组的 12 例患者中,9 例 AHA 免疫染色精氨酸加压素(AVP)分泌细胞,第 2 组的 8 例患者中有 4 例 AHA 免疫染色 AVP 分泌细胞。所有 AVP 细胞抗体阳性患者均出现亚临床/临床 CDI;相比之下,4 例 GH/ACTH 缺乏但 APA 仅染色 GH 分泌细胞的患者中,AHA 靶向 CRH 分泌细胞。
淋巴细胞性垂体炎患者发生 CDI 似乎是由于自身免疫性下丘脑受累,而不是垂体炎症过程的扩大。在这些患者中搜索 AVP 抗体可能有助于识别那些易发生自身免疫性 CDI 的患者。在一些 GH/ACTH 缺乏但 APA 仅靶向 GH 分泌细胞的患者中检测到靶向 CRH 分泌细胞的 AHA 表明,针对下丘脑的自身免疫攻击也共同导致了他们的垂体功能减退症。